According to the research report of CMB International, at the American Society of Clinical Oncology (ASCO) annual meeting, Core product SKB264 of Chia Tai Life Sciences (06990.HK) is expected to achieve better efficiency in its phase III trial and is expected to be widely used in non-small cell lung cancer. In addition, the strong results of SKB264's phase III clinical trial for triple-negative breast cancer will help it obtain approval in mainland China.

CMB International has raised the target price of the company from 200.77 yuan to 246.13 yuan and maintained a "buy" rating. It is expected that the company will record losses of 659 million yuan, 786 million yuan and 726 million yuan from 2024 to 2026.